---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-082902"
form_type: "8-K"
ticker: "EWTX"
cik: "0001710072"
company_name: "Edgewise Therapeutics, Inc."
filed_at: "2026-07-13T12:37:12+00:00"
generated_at: "2026-07-13T12:40:11.151239+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Edgewise completes $1.55B sale of muscular dystrophy program to Servier; up to $2.65B total

## Summary
- Sold sevasemten and muscular dystrophy program to Servier for $1.55B upfront plus up to $1.1B in milestones ($2.65B total).
- Company refocuses on cardiovascular pipeline: EDG-7500 (HCM), EDG-15400 (HFpEF), and EDG-003 (undisclosed).
- Upfront proceeds expected to fully fund EDG-7500 development through potential approval.
- Plans to initiate Phase 3 trial for EDG-7500 in Q4 2026 and Phase 2 trial for EDG-15400 in HFpEF.
- Core muscular dystrophy employees offered positions at Servier to ensure continuity.

## SEC filing metadata
- accession: 0001104659-26-082902
- form_type: 8-K
- ticker: EWTX
- cik: 0001710072
- company_name: Edgewise Therapeutics, Inc.
- filed_at: 2026-07-13T12:37:12+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710072/000110465926082902/0001104659-26-082902-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710072/000110465926082902/tm2620181d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-082902
- JSON: https://secwatch.observer/filing/0001104659-26-082902.json
- Plain text: https://secwatch.observer/filing/0001104659-26-082902.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.